Download File - JOHN J. HADDAD, Ph.D.

126 Schroter and Minev
42. Minev BR, McFarland BJ, Spiess PJ, et al. Insertion signal sequence fused to
minimal peptides elicits specific CD8þ T-cell responses and prolongs survival of
thymoma-bearing mice. Cancer Res 1994; 54:4155–4161.
43. Adotevi O, Mollier K, Neuveut C, et al. Immunogenic HLA-B*0702-restricted
epitopes derived from human telomerase reverse transcriptase that elicit antitumor
cytotoxic T-cell responses. Clin Cancer Res 2006; 12(10):3158–3167.
44. Brunsvig PF, Aamdal S, Gjertsen MK, et al. Telomerase peptide vaccination: a phase
I/II study in patients with non-small cell lung cancer. Cancer Immunol Immunother
2006; 55(12):1553–1564.
45. Jager E, Ringhoffer M, Arand M, et al. Cytolytic T cell reactivity against melanomaassociated
differentiation antigens in peripheral blood of melanoma patients and
healthy individuals. Melanoma Res 1996; 6:419–425.
46. Rivoltini L, Kawakami Y, Sakaguchi K, et al. Induction of tumor-reactive CTL from
peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro
stimulation with an immunodominant peptide of the human melanoma antigen
MART-1. J Immunol 1995; 154(5):2257–2265.
47. Visseren MJ, van Elsas A, van der Voort EI, et al. CTL specific for the tyrosinase
autoantigen can be induced from healthy donor blood to lyse melanoma cells.
J Immunol 1995; 154(8):3991–3998.
48. Marchand M, Weynants P, Rankin E, et al. Tumor regression responses in melanoma
patients treated with a peptide encoded by gene MAGE-3 [letter]. Int J Cancer 1995;
63:883–885.
49. Marchand M, van Baren N, Weynants P, et al. Tumor regressions observed in
patients with metastatic melanoma treated with an antigenic peptide encoded by gene
MAGE-3 and presented by HLA-A1. Int J Cancer 1999; 80(2):219–230.
50. Salgaller ML, Afshar A, Marincola FM, et al. Recognition of multiple epitopes in the
human melanoma antigen gp100 by peripheral blood lymphocytes stimulated in vitro
with synthetic peptides. Cancer Res 1995; 55:4972–4979.
51. Mukherji B, Chakraborty NG, Yamasaki S, et al. Induction of antigen-specific cytolytic
T cells in situ in human melanoma by immunization with synthetic peptide-pulsed
autologous antigen presenting cells. Proc Natl Acad Sci U S A 1995; 92:8078–8082.
52. Jaeger E, Bernhard H, Romero P, et al. Generation of cytotoxic T-cell responses with
synthetic melanoma-associated peptides in vivo: implications for tumor vaccines
with melanoma-associated antigens. Int J Cancer 1996; 66:162–169.
53. Jager E, Gnjatic S, Nagata Y, et al. Induction of primary NY-ESO-1 immunity:
CD8þ T lymphocyte and antibody responses in peptide-vaccinated patients with
NY-ESO-1þ cancers. PNAS 2000; 97(22):12198–12202.
54. Gjertsen MK, Bakka A, Breivik J, et al. Ex vivo ras peptide vaccination in patients
with advanced pancreatic cancer: results of a phase I/II study. Int J Cancer 1996;
65:450–453.
55. Celis E. Overlapping human leukocyte antigen class I/II binding peptide vaccine for
the treatment of patients with stage IV melanoma: evidence of systemic immune
dysfunction. Cancer 2007; 110(1):203–214.
56. Noguchi M, Yao A, Harada M, et al. Immunological evaluation of neoadjuvant
peptide vaccination before radical prostatectomy for patients with localized prostate
cancer. Prostate 2007; 67(9):933–942.
57. Noguchi M, Mine T, Yamada A, et al. Combination therapy of personalized peptide
vaccination and low-dose estramustine phosphate for metastatic hormone refractory